MicroPort Scientific Corporation provided earnings guidance for the second half and full year of 2020. For 2020 and full year, first one, let's say, the revenue. The outbreak of COVID-19 virus since the beginning of 2020 is a very challenging situation faced by society, both in China and globally. The management has been closely monitor its development and evaluating the impact on operating results of the group. In Q1, the company sales were affected as procedures volumes slumped in China. However, in Q2, the company have seen a notable ramp-up in group revenue, and such recovery trends strengthened into July and August. Based on current information available, the company anticipates that group revenue will continue to improve in the Third Quarter and Q4, and that the full year revenue will be largely in line with last year. While the segments operating in the China market will achieve sales growth at a single rate. But the international business, example, the orthopedics and the CRM segments, may undergo a decline in revenue due to uncertainty of the COVID-19 development in the U.S. and EU market. First one, the Cardiovascular business. It experienced a significant revenue decline by 29% in first half year. However, given the strong recovery of Firehawk and Firebird2 witnessed in the China market since middle of March, the company expects its full year revenue turn to grow by single-digit year-on-year, which is consistent with previous guidance. As for the Orthopedics segment, the company estimate the global revenue of 2020 to decline by high single digits. Within this, for the international Orthopedics business, the company have seen the greatest hit of COVID-19 to the U.S. and the EU market in April. With first half year, the revenue down by 24% year-on-year. However, since May, there has been continued sequentially increase in surgery volumes, showing a gradual recovery in those markets. Based on current information available, the company anticipated a recovery trend to continue into the rest of the year, and the full year revenue of international orthopedics business is expected to decline by approximately 10%.